Video Experimental Relacionado

Updated: Jan 13, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Estudio MDX-2001-101: protocolo de ensayo clínico de fase I/IIa, multicéntrico, de primera en humanos, abierto, que

Ecaterina Dumbrava¹, Anna Minchom², Jason Henry³

¹Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Future oncology (London, England)

|January 6, 2026

Resumen

MDX2001, un novedoso anticuerpo tetraspecífico, se dirige al factor de transición epitelial mesenquimal celular (c-MET) y al antígeno de trofoblasto 2 (TROP2) para dirigir las células T a los tumores. Este anticuerpo muestra una potente actividad antitumoral y se evaluará en un ensayo clínico de fase I/IIa.

Área de la Ciencia:

Oncología
Inmunoterapia
Ingeniería de Anticuerpos

Sus antecedentes:

MDX2001 es un anticuerpo tetraspecífico activador-expansor de células T.
Se dirige al factor de transición epitelial mesenquimal celular (c-MET), al antígeno de trofoblasto 2 (TROP2), a CD3 y a CD28.
MDX2001 ha mostrado una potente actividad antitumoral en estudios preclínicos en diversos tipos de tumores.

Objetivo del estudio:

Evaluar la seguridad y tolerabilidad del MDX2001 en pacientes con tumores sólidos avanzados.
Evaluar los efectos antitumoral del MDX2001.
Determinar la dosis máxima tolerada (DMT) y la dosis recomendada para la fase 2 (DRF2).

Principales métodos:

El estudio MDX-2001-101 es un ensayo clínico multicéntrico, abierto, de fase I/IIa.
La fase Ia implica la escalada de dosis utilizando un diseño bayesiano de intervalo óptimo.
Las fases Ib y IIa implican la expansión de dosis y la expansión de indicaciones, respectivamente.

Principales resultados:

Los estudios preclínicos demostraron una potente actividad antitumoral del MDX2001.
El ensayo clínico está diseñado para evaluar la seguridad, tolerabilidad y efectos antitumoral.
Los resultados específicos del ensayo clínico están pendientes.

Conclusiones:

MDX2001 es un prometedor anticuerpo activador-expansor de células T con eficacia preclínica demostrada.
El ensayo de fase I/IIa proporcionará datos cruciales de seguridad y eficacia para tumores sólidos avanzados.
MDX2001 tiene el potencial de ofrecer una nueva opción terapéutica para pacientes con cáncer.

Palabras clave:

CD28 CD3 MDX2001 TROP2 tumor sólido avanzado c-MET activador multispecífico de células T protocolo de estudio

Más Videos Relacionados

A Melanoma Patient-Derived Xenograft Model

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

Videos de Conceptos Relacionados

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Clinical Trials

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...